Dearborn Partners LLC Invests $978,000 in Pfizer Inc. $PFE

Dearborn Partners LLC bought a new stake in Pfizer Inc. (NYSE:PFE) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 40,635 shares of the biopharmaceutical company’s stock, valued at approximately $978,000.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Keb Asset Management LLC acquired a new stake in Pfizer in the 2nd quarter worth about $26,000. HFM Investment Advisors LLC increased its position in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the last quarter. Evolution Wealth Management Inc. grew its stake in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares during the period. Finally, Abound Financial LLC acquired a new stake in shares of Pfizer during the 4th quarter worth $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 1.0%

NYSE PFE opened at $28.00 on Friday. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75. The company has a 50-day simple moving average of $25.49 and a 200-day simple moving average of $26.29. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The firm has a market capitalization of $159.62 billion, a PE ratio of 36.85 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm earned $0.78 EPS. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer’s payout ratio is currently 226.32%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

Analysts Set New Price Targets

PFE has been the topic of several research reports. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and cut their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research note on Tuesday, June 9th. UBS Group reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. Finally, Wolfe Research reissued an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.